Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 15/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24433967 | 0.88 | FAAH (0.41) | FAAHCNR1 | |
| SCHEMBL24433946 | 0.85 | FAAH (0.34) | FAAHLMNATSHRALOX12HTT | |
| SCHEMBL23912853 | 0.81 | LMNA (0.47) | FAAHCNR2LMNATSHRALOX12 | |
| SCHEMBL4075603 | 0.78 | LMNA (0.52) | FAAHCNR1CNR2CYP2C19KCNH2 | |
| SCHEMBL4080235 | 0.76 | FAAH (0.42) | FAAHCNR1CNR2CYP2C19KCNH2 | |
| SCHEMBL24454992 | 0.71 | CNR2 (0.40) | CNR2LMNATSHRALOX12HTT | |
| SCHEMBL4080228 | 0.70 | CNR1 (0.48) | FAAHCNR1CNR2 | |
| SCHEMBL23912846 | 0.70 | FAAH (0.43) | FAAHCNR1 | |
| SCHEMBL4182413 | 0.70 | LMNA (0.51) | FAAHCNR1CNR2LMNATSHR | |
| SCHEMBL4182411 | 0.70 | LMNA (0.51) | FAAHCNR1CNR2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220151990-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | ANEBULO PHARMACEUTICALS, INC. | 2022-05-19 | — | — | US | disclosed |
| US-11141404-B1 | Formulations and methods for treating acute cannabinoid overdose | ANEBULO PHARMACEUTICALS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151990-A1 | FORMULATIONS AND METHODS FOR TREATING ACUTE CANNABINOID OVERDOSE | CNR1, CNR2, FAAH | FAAH 3/4885CNR1 1/4885CNR2 2/4885 |
| US-11141404-B1 | Formulations and methods for treating acute cannabinoid overdose | CNR1, CNR2, FAAH | FAAH 3/4885CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.